Philips launches LumiGuide 3D Device Guidance across US and Europe for radiation-free navigation

USA— Royal Philips, a global leader in health technology, has announced the expanded commercial availability of LumiGuide 3D Device Guidance across Europe and the United States.

This innovative system is the world’s first real-time, AI-powered, light-based 3D navigation solution designed for image-guided therapy.

The announcement follows Philips’ recent introduction of the BlueSeal Horizon at RSNA 2025, marking a significant advancement with wide-ranging impacts for healthcare providers and patients worldwide.

LumiGuide revolutionizes radiation-free navigation by enabling physicians to visualize and guide devices inside the body using light instead of continuous X-ray imaging.

This breakthrough technology was also unveiled at RSNA 2025, and its broader commercial release reflects Philips’ commitment to enhancing radiation safety and reducing patient and staff exposure during image-guided procedures.

Fully integrated with Philips’ Azurion platform—a leading image-guided therapy system known for driving innovation across clinical specialties—LumiGuide enhances procedural outcomes by improving efficiency, safety, and precision.

Alongside other AI-enabled tools and therapeutic devices on the Azurion platform, LumiGuide offers clinicians a powerful suite for planning and carrying out complex interventions with greater confidence.

Adam W. Beck, MD, Professor and Director of the Division of Vascular Surgery & Endovascular Therapy at the University of Alabama at Birmingham, shared his experience, stating that he has performed over 160 fenestrated and branched aortic procedures using LumiGuide.

He noted that the system significantly increases efficiency, shortens procedure times, and almost eliminates the need for fluoroscopy.

Powered by Philips Fiber Optic RealShape (FORS) technology, LumiGuide is the first solution to use light to visualize the shape and position of guidewires and compatible endovascular catheters in real time and in 3D, without X-ray.

By reflecting light through an optical fiber within the guidewire, LumiGuide produces high-resolution, full-color images from any angle, giving physicians instant orientation during complex endovascular procedures.

Additionally, AI algorithms quickly and precisely align images with the patient’s anatomy, enabling clinicians to navigate with accuracy while drastically reducing radiation exposure for everyone involved.

Using this advanced system, complex procedures like aortic repairs can be completed up to 37% faster and with up to a 56% reduction in dose area product (DAP), which measures radiation exposure.

Stacey Beske, Business Leader for Image-Guided Therapy Devices at Philips, emphasized that moving LumiGuide from limited to full commercial availability is a vital step for expanding access to cutting-edge image-guided therapy worldwide.

Atul Gupta, MD, Philips’ Chief Medical Officer for Diagnosis & Treatment, added that extending this light-based navigation technology to more hospitals helps clinicians manage complex vascular diseases precisely and safely, while also reducing radiation risks for patients and medical teams.

Built on Philips’ long-standing leadership in image-guided therapy and the trusted Azurion platform, LumiGuide exemplifies the company’s drive to advance minimally invasive treatments through the integration of intelligent systems that deliver real-time insights, precise navigation, and efficient workflows.

The Azurion platform supports over 6.4 million patients annually across more than 80 countries, providing high-quality, low-dose imaging that enhances procedural productivity.

LumiGuide complements other AI-enabled innovations such as DeviceGuide and VeriSight 3D ICE, combining intelligence and imaging to deliver the next generation of procedural accuracy within the Azurion ecosystem.

Following a successful limited release in late 2023, LumiGuide will be widely available from January 2026 in major European markets and the United States.

It has already supported over 2,000 clinical cases, benefiting from integration with Philips’ Azurion image-guided therapy platform.

Philips continues to invest in clinical research to optimize LumiGuide’s everyday use, building on its broader efforts to reduce or eliminate radiation exposure during image-guided procedures.

Alongside other technologies like Azurion with ClarityIQ, DoseAware, EchoNavigator, and programs such as the RADIQAL trial, LumiGuide highlights Philips’ commitment to delivering safer, more efficient, and sustainable interventional solutions.